ICLR
ICON Public Limited Company
$174.19
+3.60% 2026-10-20
Healthcare
ICLRSPY
1W
+6.0%
1M
+6.1%
3M
+4.5%
6M
+51.2%
YTD
-4.4%
1Y
-7.6%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsAnalysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Zacks · 13h ago
Icon's 2027 Outlook Supported by Strong Bookings as Growth Questions Persist, RBC Says
MT Newswires · Oct 12
ICON Schedules Third Quarter 2026 Earnings Conference Call
Business Wire · Oct 08
UBS Downgrades ICON to Neutral From Buy
MT Newswires · Sep 30
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure
Insider Monkey · Sep 22
Key stats
Market cap$13.4B
P/E (trailing)183.4
P/E (forward)14.8
52-week range66.57 – 203.91
Revenue growth (YoY, latest qtr)+1.2%
Dividend yield0.00%
Analyst consensusBuy (17)
Mean price target$189.41 (+9%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-10-27 · after close · EPS est 2.63
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | 2.52 | 2.56 | +1.7% |
| 2026-06-23 | 2.43 | 2.50 | +3.0% |
| 2026-05-27 | 3.11 | 2.52 | -18.9% |
| 2025-10-22 | 3.28 | 3.31 | +1.0% |
| 2025-07-23 | 3.18 | 3.26 | +2.4% |
| 2025-04-30 | 3.09 | 3.19 | +3.1% |
| 2025-02-19 | 3.43 | 3.43 | +0.1% |
| 2024-10-23 | 3.85 | 3.35 | -13.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.1B | +1.2% |
| 2026-03-31 | $2.0B | – |
| 2025-12-31 | $2.2B | – |
| 2025-09-30 | $2.1B | – |
| 2025-06-30 | $2.0B | – |
Analyst actions
Citigroup
PT $175
2026-09-18 · main
Neutral → NeutralPT $175
Citigroup
PT $180
2026-07-31 · main
Neutral → NeutralPT $180
Truist Securities
PT $209
2026-07-31 · reit
Buy → BuyPT $209
Truist Securities
PT $207
2026-06-30 · up
Hold → BuyPT $207
Mizuho
PT $190
2026-06-26 · main
Outperform → OutperformPT $190
Citigroup
PT $165
2026-06-25 · main
Neutral → NeutralPT $165
Insider trades
Mccague Eugene Pacelli
$569.6K
Director · 2026-09-17
SELL$569.6K
Murphy Ronan Martin
$875.9K
Director · 2026-09-17
SELL$875.9K
Climax John Dr
$875.9K
Director · 2026-09-16
SELL$875.9K
Whitaker Anne Clem
$14.3K
Director · 2026-08-11
SELL$14.3K
Whitaker Anne Clem
$15.7K
Director · 2026-08-11
SELL$15.7K
Whitaker Anne Clem
$97.0K
Director · 2026-08-11
SELL$97.0K
Whitaker Anne Clem
$11.1K
Director · 2026-08-11
SELL$11.1K
O'Neill Julie
$15.5K
Director · 2026-08-11
SELL$15.5K
O'Neill Julie
$17.2K
Director · 2026-08-11
SELL$17.2K
O'Neill Julie
$105.6K
Director · 2026-08-11
SELL$105.6K
O'Neill Julie
$12.1K
Director · 2026-08-11
SELL$12.1K
Murray Ciaran
$45.6K
Director · 2026-08-11
SELL$45.6K
Stats refreshed 2026-10-20 18:02:50 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteauCoteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.